U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07589257) titled 'A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma' on May 08.
Brief Summary: To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG
Study Start Date: May 07
Study Type: INTERVENTIONAL
Condition:
Diffuse Midline Glioma, H3 K27M-Mutant
Diffuse Intrinsic Pontine Glioma
Intervention:
DRUG: VRT106 for injection
VRT106, iv
Recruitment Status: RECRUITING
Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Da...